nemtabrutinib + venetoclax

Nemtabrutinib + venetoclax is an investigational oral combination therapy comprising two small molecules: nemtabrutinib, a next-generation, reversible and non-covalent Bruton’s tyrosine kinase (BTK) inhibitor, and venetoclax, a selective inhibitor of B cell lymphoma 2 (BCL-2). This combination is being evaluated primarily for relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Nemtabrutinib works by inhibiting BTK, thereby blocking B cell receptor (BCR) signaling in CLL cells, including those resistant to covalent BTK inhibitors. Venetoclax targets the anti-apoptotic protein BCL-2, promoting apoptosis of malignant B cells. Preclinical and early clinical evidence suggests potential synergy or additive activity when these agents are combined, supporting ongoing phase 3 investigation.[1][2][3][5][7][9]